相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer immunotherapy trial design with cure rate and delayed treatment effect
Jing Wei et al.
STATISTICS IN MEDICINE (2020)
Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point
Bo Huang et al.
PHARMACEUTICAL STATISTICS (2018)
Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate
Shufang Liu et al.
PHARMACEUTICAL STATISTICS (2018)
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations
Lu Tian et al.
BIOMETRICS (2018)
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
Kyongsun Pak et al.
JAMA ONCOLOGY (2017)
On the Restricted Mean Survival Time Curve in Survival Analysis
Lihui Zhao et al.
BIOMETRICS (2016)
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
Ludovic Trinquart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
Hajime Uno et al.
ANNALS OF INTERNAL MEDICINE (2015)
Predicting the restricted mean event time with the subject's baseline covariates in survival analysis
Lu Tian et al.
BIOSTATISTICS (2014)
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study
Lihui Zhao et al.
CLINICAL TRIALS (2012)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
分享论文
